Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | May 14, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | CARDAX, INC. | |
Entity Central Index Key | 0001544238 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2021 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 802,516 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2021 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS | ||
Cash | $ 58,650 | $ 19,179 |
Accounts receivable, net | 36,749 | |
Inventories | 962,859 | 994,319 |
Deposits and other assets | 3,063 | 3,063 |
Prepaid expenses | 26,814 | 105,238 |
Total current assets | 1,088,135 | 1,121,799 |
INTANGIBLE ASSETS, net | 290,225 | 302,411 |
RIGHT OF USE ASSETS | 962 | |
TOTAL ASSETS | 1,378,360 | 1,425,172 |
CURRENT LIABILITIES | ||
Accrued payroll and payroll related expenses, current portion | 4,464,942 | 4,362,381 |
Accounts payable and accrued expenses | 1,908,663 | 1,689,352 |
Fees payable to directors | 418,546 | 418,546 |
Accrued separation costs, current portion | 12,000 | 12,000 |
Current portion of related party notes payable | 1,769,000 | 769,000 |
Current portion of notes payable | 211,300 | 211,300 |
Related party convertible notes payable, net of discount | 1,563,195 | 1,334,296 |
Convertible notes payable, net of discount | 1,640,619 | 1,468,531 |
Employee settlement | 50,000 | 50,000 |
Lease liability, current portion | 962 | |
Derivative liability on convertible notes payable | 412,163 | 235,165 |
Total current liabilities | 12,450,428 | 10,551,533 |
NON-CURRENT LIABILITIES | ||
Related party notes payable, less current portion | 1,000,000 | |
Notes payable, less current portion | 211,359 | |
Accrued separation costs, less current portion | 68,635 | 71,635 |
Total non-current liabilities | 279,994 | 1,071,635 |
COMMITMENTS AND CONTINGENCIES | ||
Total liabilities | 12,730,422 | 11,623,168 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock - $0.001 par value; 50,000,000 shares authorized, 2,000 and 0 shares issued and outstanding as of March 31, 2021, and December 31, 2020, respectively | 2 | |
Common stock - $0.001 par value; 400,000,000 shares authorized, 802,516 and 794,183 shares issued and outstanding as of March 31, 2021, and December 31, 2020, respectively | 802 | 794 |
Additional paid-in-capital | 62,121,114 | 61,893,072 |
Accumulated deficit | (73,473,980) | (72,091,862) |
Total stockholders' deficit | (11,352,062) | (10,197,996) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 1,378,360 | $ 1,425,172 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, shares issued | 2,000 | 0 |
Preferred stock, shares outstanding | 2,000 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 400,000,000 | 400,000,000 |
Common stock, shares issued | 802,516 | 794,183 |
Common stock, shares outstanding | 802,516 | 794,183 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
REVENUES, net | $ 104,574 | $ 142,813 |
COST OF GOODS SOLD | 38,378 | 62,995 |
GROSS PROFIT | 66,196 | 79,818 |
OPERATING EXPENSES: | ||
Salaries and wages | 286,883 | 373,292 |
Professional fees | 190,447 | 222,316 |
Selling, general, and administrative expenses | 119,561 | 168,413 |
Stock based compensation | 144,062 | 177,813 |
Research and development | 88,237 | 35,282 |
Depreciation and amortization | 8,318 | 8,733 |
Total operating expenses | 837,508 | 985,849 |
Loss from operations | (771,312) | (906,031) |
OTHER INCOME (EXPENSE): | ||
Change in fair value of derivative liability | (176,998) | (3,667) |
Gain on modification of debt instruments | 3,272 | 354,791 |
Loss on abandonment of patents | (4,690) | |
Interest expense | (438,285) | (447,961) |
Gain on sale of assets | 5,895 | |
Total other income (expense), net | (610,806) | (96,837) |
Loss before the provision for income taxes | (1,382,118) | (1,002,868) |
PROVISION FOR INCOME TAXES | ||
NET LOSS | $ (1,382,118) | $ (1,002,868) |
NET LOSS PER SHARE | ||
Basic | $ (1.74) | $ (1.43) |
Diluted | $ (1.74) | $ (1.43) |
SHARES USED IN CALCULATION OF NET LOSS PER SHARE | ||
Basic | 794,183 | 700,879 |
Diluted | 794,183 | 700,879 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-In-Capital [Member] | Accumulated Deficit [Member] | Series A Preferred Stock [Member] | Total |
Balance at Dec. 31, 2019 | $ 688 | $ 59,836,818 | $ (67,036,355) | $ (7,198,849) | |
Balance, shares at Dec. 31, 2019 | 687,564 | ||||
Common stock grants to independent directors | $ 3 | 18,747 | 18,750 | ||
Common stock grants to independent directors, shares | 3,125 | ||||
Warrants granted to independent directors | 75,000 | 75,000 | |||
Stock based compensation - options | 84,063 | 84,063 | |||
Common stock grants to convertible note holders | $ 71 | 434,641 | 434,712 | ||
Common stock grants to convertible note holders, shares | 71,409 | ||||
Issuance of warrants attached to convertible notes | 2,777 | 2,777 | |||
Beneficial conversion feature issued on convertible notes | 141,391 | 141,391 | |||
Revaluation of notes payable discounts due to modification of conversion price | (214,498) | (214,498) | |||
Extinguishment of derivative liability upon repayment of convertible note | 78,200 | 78,200 | |||
Net loss | (1,002,868) | (1,002,868) | |||
Balance at Mar. 31, 2020 | $ 762 | 60,457,139 | (68,039,223) | (7,581,322) | |
Balance, shares at Mar. 31, 2020 | 762,098 | ||||
Balance at Dec. 31, 2019 | $ 688 | 59,836,818 | (67,036,355) | (7,198,849) | |
Balance, shares at Dec. 31, 2019 | 687,564 | ||||
Balance at Dec. 31, 2020 | $ 794 | 61,893,072 | (72,091,862) | (10,197,996) | |
Balance, shares at Dec. 31, 2020 | 794,183 | ||||
Common stock grants to independent directors | $ 8 | 18,742 | 18,750 | ||
Common stock grants to independent directors, shares | 8,333 | ||||
Warrants granted to independent directors | 75,000 | 75,000 | |||
Stock based compensation - options | 50,312 | 50,312 | |||
Issuance of warrants attached to convertible notes | 110,450 | 110,450 | |||
Preferred stock issuance for cash | 49,998 | $ 2 | 50,000 | ||
Preferred stock issuance for cash, shares | 2,000 | ||||
Warrants issued to placement agents | 903 | 903 | |||
Stock issuance costs | (77,363) | (77,363) | |||
Extinguishment of derivative liability upon repayment of convertible note | |||||
Net loss | (1,382,118) | (1,382,118) | |||
Balance at Mar. 31, 2021 | $ 802 | $ 62,121,114 | $ (73,473,980) | $ 2 | $ (11,352,062) |
Balance, shares at Mar. 31, 2021 | 802,516 | 2,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (1,382,118) | $ (1,002,868) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 8,318 | 8,733 |
Amortization of debt discount | 322,209 | 297,656 |
Stock based compensation | 144,062 | 177,813 |
Loss on abandonment of patents | 4,690 | |
Change in fair value of derivative liability | 176,998 | 3,667 |
Gain on modification of debt instruments | (3,272) | (354,791) |
Changes in assets and liabilities: | ||
Accounts receivable | (36,749) | 85,385 |
Inventories | 31,460 | 61,271 |
Deposits and other assets | (997) | |
Prepaid expenses | 78,424 | 12,841 |
Accrued payroll and payroll related expenses | 102,561 | 101,412 |
Accounts payable and accrued expenses | 219,311 | 43,288 |
Accrued separation costs | (3,000) | (2,250) |
Net cash used in operating activities | (337,106) | (568,840) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Increase in intangible assets | (822) | (9,272) |
Net cash used in investing activities | (822) | (9,272) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from the issuance of notes payable | 211,359 | |
Proceeds from the issuance of related party convertible notes payable | 250,000 | |
Proceeds from the issuance of convertible notes payable | 150,000 | 770,000 |
Repayment of principal on convertible notes payable | (130,000) | (150,000) |
Payment of debt issuance costs | (10,000) | |
Payment of extension costs on convertible notes payable | (77,500) | |
Proceeds from the issuance of preferred stock | 50,000 | |
Payment of stock issuance costs | (76,460) | |
Net cash provided by financing activities | 377,399 | 610,000 |
NET INCREASE (DECREASE) IN CASH | 39,471 | 31,888 |
CASH AT BEGINNING OF THE PERIOD | 19,179 | 19,303 |
CASH AT END OF THE PERIOD | 58,650 | 51,191 |
SUPPLEMENTAL DISCLOSURES: | ||
Cash paid for interest | 795 | 116,341 |
Cash paid for income taxes | ||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Settlement of receivables with payables | 16,792 | |
Right of use assets funded through leases | 962 | 2,882 |
Discounts recognized on notes payable at issuance | 110,450 | 765,732 |
Extinguishment of derivative liability upon repayment of convertible notes | 78,200 | |
Revaluation of notes payable discounts due to modification of conversion price | 534,623 | |
Stock issuance cost for warrants issued to placement agents | $ 903 |
Company Background
Company Background | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Company Background | NOTE 1 – COMPANY BACKGROUND The Company’s predecessor, Cardax Pharmaceuticals, Inc. (“Holdings”), was incorporated in the State of Delaware on March 23, 2006. Cardax, Inc. (the “Company”) (OTCQB:CDXI) is a biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets dietary supplements for inflammatory health. CDX-101, the Company’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. The Company’s pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. ZanthoSyn® is a physician recommended astaxanthin dietary supplement for inflammatory health. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA. Going concern matters The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred net losses of $1,382,118 and $1,002,868 for the three-months ended March 31, 2021 and 2020, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $73,473,980 as of March 31, 2021, and has had negative cash flows from operating activities since inception. Management expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its consumer business. The Company also plans to advance the research and development of its pharmaceutical candidates and anticipates further losses in the development of its pharmaceutical business. The Company’s ability to access the capital markets is unknown during the coronavirus disease 2019 (“COVID-19”) pandemic, which may limit or prevent the funding of its operations and related obligations. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company needs to raise additional capital to carry out its business plan. During the three-months ended March 31, 2021, the Company raised $50,000 and $611,359 in gross proceeds through the issuance of preferred stock and debt securities, respectively. The Company filed a registration statement on Form S-1 on August 14, 2019, as amended September 27, 2019, and November 22, 2019, for a proposed $15 million public offering of common stock and warrants. The Company continued to take actions to advance the proposed public offering in 2020, but due to COVID-19 related travel restrictions, financial market conditions, and other considerations, the public offering was not consummated. In March 2021, the Company requested withdrawal of the registration statement from the Commission. The Company launched a private placement of preferred stock for an aggregate amount of up to $10 million with an initial closing of $50,000 on January 11, 2021; however, there can be no assurance that additional closings will be consummated. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act provides aid to small businesses through programs administered by the U.S. Small Business Administration (the “SBA”). The CARES Act established a Paycheck Protection Program (the “PPP”), under which certain small businesses are eligible for loans to fund payroll expenses, rent, and related costs. In April 2020, the Company received a PPP loan in the amount of $211,300 (see Note 7). In February 2021, the Company received a Second Draw PPP loan in the amount of $211,359 (see Note 7). Under the terms of the program, the loan amounts may be forgiven if certain terms and conditions are met. Management believes the PPP loans received by the Company will be eligible for forgiveness in accordance with the terms of the program. In April 2021, the Company received an Economic Injury Disaster Loan from the SBA in the amount of $500,000 (see Subsequent Events). The Company’s continued ability to raise capital through future equity and debt securities issuances is unknown, especially during the COVID-19 pandemic. If the Company is unable to obtain adequate capital, the Company may be required to cease operations or substantially curtail its ongoing and planned commercial activities. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on April 15, 2021 (the “Annual Report”). Revenue from contracts with customers Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2021 March 31, 2020 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 104,574 $ 142,813 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale. Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, debt issuance costs, and modifications. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt ● Debt modifications. Debt Modifications and Extinguishments Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs Other significant accounting policies There have been no other material changes to our significant accounting policies during the three-months ended March 31, 2021, as compared to the significant accounting policies described in our Annual Report. Recently issued accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on its condensed consolidated financial statements. Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows. |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | NOTE 3 – INVENTORIES Inventories consist of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Raw materials $ 759,400 $ 759,400 Finished goods 203,459 234,919 Total inventories $ 962,859 $ 994,319 As of March 31, 2021, and December 31, 2020, all raw materials were held at the manufacturer’s facility for future production. Additionally, as of March 31, 2021, and December 31, 2020, $191,721 and $227,597, respectively, in finished goods were held at the manufacturer’s facility for shipment. |
Intangible Assets, Net
Intangible Assets, Net | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets, Net | NOTE 4 – INTANGIBLE ASSETS, net Intangible assets, net, consists of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Patents $ 499,106 $ 499,106 Less accumulated amortization (265,060 ) (256,742 ) 234,046 242,364 Patents pending 56,179 60,047 Total intangible assets, net $ 290,225 $ 302,411 Patents are amortized straight-line over a period of fifteen years. Amortization expense was $8,318 and $8,733 for the three-months ended March 31, 2021 and 2020, respectively. The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved. During the three-months ended March 31, 2021, the Company abandoned one patent application resulting in a loss of $4,690. The Company has 28 issued patents, including 13 in the U.S. and 15 outside the U.S. that will expire between 2023 and 2028, subject to patent term extensions. The Company also has three additional patents pending that if issued would extend patent coverage in the U.S. and outside the U.S. to 2039-2041. |
Accrued Separation Costs
Accrued Separation Costs | 3 Months Ended |
Mar. 31, 2021 | |
Payables and Accruals [Abstract] | |
Accrued Separation Costs | NOTE 5 – ACCRUED SEPARATION COSTS On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. As of March 31, 2021, $80,635 remains outstanding of which $12,000 is due within one-year and is reflected as a current liability. |
Related Party Notes Payable
Related Party Notes Payable | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Notes Payable | NOTE 6 – RELATED PARTY NOTES PAYABLE Related party notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note 500,000 500,000 Promissory note. - - Promissory note. 94,000 94,000 Promissory note. 100,000 100,000 Total related party notes payable 1,769,000 1,769,000 Less current portion (1,769,000 ) (769,000 ) Long term related party notes payable $ - $ 1,000,000 Interest expense The Company incurred interest charges on these related party notes payable of $48,175 and $45,593 during the three-months ended March 31, 2021 and 2020, respectively. The aggregate amount of accrued and unpaid interest on these related party notes payable was $165,001 and $63,143 as of March 31, 2021 and 2020, respectively. Maturities These related party notes payable mature within one year of March 31, 2021. |
Notes Payable
Notes Payable | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Notes Payable | NOTE 7 – NOTES PAYABLE On April 20, 2020, the Company received a Paycheck Protection Program (“PPP”) loan under the U.S. Small Business Administration (the “SBA”) for $211,300, which was funded on April 22, 2020. Under the terms of the program, up to 100% of the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures two (2) years from issuance and accrues interest at 1% per annum with principal and interest payments deferred until the SBA remits the Company’s loan forgiveness amount to the lender. The Company applied for forgiveness in May 2021. Management believes the loan is eligible for forgiveness in accordance with the terms of the program. If the loan amount is not forgiven in full, the Company expects to repay any unforgiven amount within one year of March 31, 2021, so the loan amount is recorded as a current liability. On July 14, 2020, the Company issued a note payable in the amount of $25,000. This note accrued interest at 12% per annum, payable at maturity, and matured on July 31, 2020. On July 31, 2020, this note was repaid in full. On February 6, 2021, the Company received a Second Draw Paycheck Protection Program (“PPP”) loan for $211,359, which was funded on February 8, 2021. Under the terms of the program, the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures five (5) years from issuance and accrues interest at 1% per annum with principal and interest payments deferred until the SBA remits the Company’s loan forgiveness amount to the lender. If the Company does not apply for loan forgiveness, payments will be deferred 10 months after the end of the covered period for loan forgiveness (24 weeks following loan disbursement). Management believes the loan will be eligible for forgiveness in accordance with the terms of the program. Interest expense The Company incurred interest charges on these notes payable of $822 and $0 during the three-months ended March 31, 2021 and 2020, respectively. The aggregate amount of accrued and unpaid interest on these notes payable was $2,289 and $0 as of March 31, 2021 and 2020, respectively. Other The Company received an Economic Injury Disaster Loan (“EIDL”) from the SBA in the amount of $500,000 in April 2021 (see Subsequent Events). The Company received an EIDL advance amount of $10,000 during the year-ended December 31, 2020. According to the SBA, the advance does not need to be repaid, so the Company recognized the advance as other income. |
Related Party Convertible Notes
Related Party Convertible Notes Payable | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Convertible Notes Payable | NOTE 8 – RELATED PARTY CONVERTIBLE NOTES PAYABLE Related party convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-02. $ 815,217 $ 815,217 Convertible note 2019-07. 217,391 217,391 March 31, 2021 (Unaudited) December 31, 2020 Officer convertible note. 100,000 100,000 Convertible note 2020-11. 271,739 271,739 Convertible note 2020-16. - - Convertible note 2021-02. 100,000 - Convertible note 2021-03. 150,000 - Related party convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Total related party convertible notes payable 1,654,347 1,404,347 Less original issue discounts (104,347 ) (104,347 ) Related party convertible notes payable, net 1,550,000 1,300,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (448,710 ) (386,310 ) Plus amortization of discounts 461,905 420,606 Total related party convertible notes payable, net $ 1,563,195 $ 1,334,296 Discounts Total discounts (original issue discounts plus discounts for conversion rights, beneficial conversion features, and detachable warrants) of $553,057 are amortized using the interest method, which resulted in amortization recorded as interest expense of $41,299 and $112,446 for the three-months ended March 31, 2021 and 2020, respectively, with total accumulated amortization equal to $461,905 as of March 31, 2021. Modifications The Company evaluated changes to the terms of certain related party convertible notes payable in accordance with FASB ASC No. 470-50, Debt Modifications and Extinguishments In February 2020, the Company adjusted the conversion price of certain related party convertible notes payable in accordance with their terms, which triggered modification accounting and resulted in a gain of $258,903. On June 30, 2020, the Company extended the maturity dates of the related party convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. On January 1, 2021, amendments to certain related party convertible notes payable as described in the table above provided that interest shall be payable at maturity. All other terms remain unchanged. The amendments were not considered material modifications, and as a result, were not considered accounting extinguishments in the period the notes were modified. Interest expense The Company incurred interest charges on these related party convertible notes payable of $31,352 and $24,020 for the three-months ended March 31, 2021 and 2020, respectively. The aggregate amount of accrued and unpaid interest on these related party convertible notes payable was $41,376 and $8,183 as of March 31, 2021 and 2020, respectively. Maturities These related party convertible notes payable mature within one year of March 31, 2021. |
Convertible Notes Payable
Convertible Notes Payable | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Convertible Notes Payable | NOTE 9 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-01. $ - $ - Convertible note 2019-03. 108,696 108,696 Convertible note 2019-04. 54,348 54,348 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-05. 27,174 27,174 Convertible note 2019-06. 27,174 27,174 Convertible note 2019-08. 108,696 108,696 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-09. 27,174 27,174 Convertible note 2019-10. 16,304 16,304 Convertible note 2020-01. 10,870 10,870 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-02. - 133,272 Convertible note 2020-03. 52,632 52,632 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-04. - - Convertible note 2020-05. 260,000 260,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-06. 500,000 500,000 Convertible note 2020-07. 100,000 100,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-08. 25,000 25,000 Convertible note 2020-09. 100,000 100,000 Convertible note 2020-10. 15,000 15,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-12. 25,000 25,000 Convertible note 2020-13. 108,696 108,696 Convertible note 2020-14. 60,000 60,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-15. 20,000 20,000 Convertible note 2020-17. 55,556 55,556 Convertible note 2021-01. 55,556 - March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2021-04. 100,000 - Total convertible notes payable 1,857,876 1,835,592 Less original issue discounts (112,876 ) (107,320 ) Convertible notes payable, net 1,745,000 1,728,272 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants (1,162,604 ) (1,062,054 ) Plus amortization of discounts 1,058,223 802,313 Total convertible notes payable, net $ 1,640,619 $ 1,468,531 Discounts Total discounts (original issue discounts plus discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants) of $1,275,480 are amortized using the interest method, which resulted in amortization recorded as interest expense of $280,910 and $185,210 for the three-months ended March 31, 2021 and 2020, respectively, with total accumulated amortization equal to $1,058,223 as of March 31, 2021. Modifications The Company evaluated changes to the terms of certain convertible notes payable in accordance with FASB ASC No. 470-50, Debt Modifications and Extinguishments In February 2020, the Company adjusted the conversion price of a convertible note payable in accordance with its terms, which triggered modification accounting and resulted in a gain of $95,888. On June 30, 2020, the Company extended the maturity dates of certain convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. In September 2020, the Company adjusted the conversion price of a convertible note payable in accordance with its terms, which triggered modification accounting and resulted in a gain of $40,133. In November 2020, the Company extended the maturity date of a certain convertible note payable as described in the table above. Management compared the present value of this note before and after the extension, noting that the change in present value was greater than 10%, which triggered an accounting extinguishment in such period. In November 2020, the Company extended the maturity date and the fixed conversion price and prepayment period of certain convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. On January 1, 2021, amendments to certain convertible notes payable as described in the table above provided that interest shall be payable at maturity. All other terms remain unchanged. The amendments were not considered material modifications, and as a result, were not considered accounting extinguishments in the period the notes were modified. In January and March 2021, the Company extended the maturity date of a certain convertible note payable as described in the table above. Management compared the present value of this note before and after each extension, noting that the change in present value was less than 10%. As such, this note was determined to not be substantially different and no change in value was recognized. In January, February, and March 2021, the Company extended the fixed conversion price and prepayment period of a certain convertible note payable as described in the table above. Management compared the present value of this note before and after each extension, noting that the change in present value was less than 10%. As such, this note was determined to not be substantially different and no change in value was recognized. Interest expense The Company incurred interest charges on these convertible notes payable of $39,452 and $39,426 during the three-months ended March 31, 2021 and 2020, respectively. The aggregate amount of accrued and unpaid interest on these convertible notes payable was $102,310 and $31,370 as of March 31, 2021 and 2020, respectively. Maturities These convertible notes payable mature within one year of March 31, 2021. |
Derivative Financial Instrument
Derivative Financial Instruments | 3 Months Ended |
Mar. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | NOTE 10 – DERIVATIVE FINANCIAL INSTRUMENTS The Company has identified the embedded derivatives related to the convertible notes described in Notes 8 and 9. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of these derivative liabilities as of the issuance date of those convertible notes and each subsequent reporting date as well as upon modification, repayment, or extinguishment of the convertible notes. Derivative liabilities are eliminated upon repayment or extinguishment of the convertible notes and recorded as an adjustment to additional paid in capital. The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments were as follows for the: Three-months ended Year ended December 31, 2020 Dividend yield 0 % 0 % Risk-free rate 0.07 % 0.10% - 1.43 % Volatility 158 % 147% - 190 % Expected term 1 year 1 year The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of valuation for the expected term of the derivative liabilities to be valued. The expected volatility is calculated based on the historical volatility of the Company. The Company recognized derivative liabilities as follows: Derivative liabilities as of January 1, 2020 $ 827,314 Valuation upon issuance 433,672 Revaluation upon modification (344,137 ) Change in fair value (222,707 ) Elimination upon extinguishment (458,977 ) Derivative liabilities as of December 31, 2020 235,165 Change in fair value 176,998 Derivative liabilities as of March 31, 2021 $ 412,163 The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 Change in Fair Value December 31, 2020 $ - $ - $ 235,165 $ (222,707 ) March 31, 2021 $ - $ - $ 412,163 $ 176,998 |
Stockholders' Deficit
Stockholders' Deficit | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Stockholders' Deficit | NOTE 11 – STOCKHOLDERS’ DEFICIT Preferred stock issuance On January 11, 2021, the Company sold 2,000 shares of Series A Preferred Stock for an aggregate purchase price of $50,000. In accordance with the Certificate of Designation of Series A Preferred Stock dated January 7, 2021: (i) each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, from and after October 15, 2022, into shares of common stock; (ii) all outstanding shares of Series A Preferred Stock shall be automatically converted into shares of common stock in the event any of the Company’s securities are listed for trading on any national exchange; and (iii) the Company may redeem any or all of the outstanding shares of Series A Preferred Stock at any time after October 15, 2023. Reverse stock split On January 15, 2020, the Company effected a 200-for-1 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock. The Reverse Stock Split did not change the number of shares of common stock authorized for issuance, the par value of the common stock, or any other terms of the common stock. No fractional shares were issued in the Reverse Stock Split and any remaining share fractions were rounded up to the next whole share. Under the terms and conditions of outstanding options, warrants, and other convertible securities, the number of underlying shares of common stock and the exercise prices or conversion prices thereof were proportionately adjusted for the Reverse Stock Split. All share and per share amounts reported in the condensed consolidated financial statements reflect the Reverse Stock Split. Conversion of convertible note On December 17, 2020, the Company issued 18,000 shares of restricted common stock upon the full conversion of a convertible note in the principal amount of $90,000. Shares outstanding As of March 31, 2021, and December 31, 2020, the Company had a total of 802,516 and 794,183 shares of common stock outstanding, respectively. The Company also had 2,000 and 0 shares of preferred stock outstanding as of March 31, 2021, and December 31, 2020. |
Stock Grants
Stock Grants | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Stock Grants | NOTE 12 – STOCK GRANTS Stock grants to convertible note holders During the year ended December 31, 2020, the Company granted convertible note holders an aggregate of 81,409 shares of restricted common stock as consideration for commitment fees (“commitment shares”). 27,777 commitment shares were cancelled upon repayment of a convertible note in accordance with its terms and another 27,777 commitment shares are returnable upon repayment of a convertible note in accordance with its terms. During the year ended December 31, 2020, the Company granted a convertible note holder 6,250 shares of restricted common stock as consideration for extension fees. There were no such grants during the three-months ended March 31, 2021. Director stock grants During the three-months ended March 31, 2021 and 2020, the Company granted an independent director an aggregate of 8,333 and 3,125 shares of restricted common stock, which were fully vested upon issuance. The expense recognized for these grants based on the fair value on the grant date was $18,750 for the three-months ended March 31, 2021 and 2020. During the year ended December 31, 2020, the Company granted its independent directors an aggregate of 28,737 shares of restricted common stock. These shares were fully vested upon issuance. |
Stock Option Plans
Stock Option Plans | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock Option Plans | NOTE 13 – STOCK OPTION PLANS On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares reserved under this plan upon adoption was 152,101. On April 16, 2015, the majority stockholder of the Company approved an increase in the shares reserved under this plan by 75,000 shares. On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year. Accordingly, effective as of January 1, 2020, the shares reserved under this plan were increased by 27,000 shares, and effective as of January 1, 2021, the shares reserved under this plan were increased by 31,000 shares. An aggregate of 279,101 shares of common stock were reserved for issuance under this plan as of December 31, 2020, and an aggregate of 310,101 shares of common stock were reserved for issuance under this plan as of March 31, 2021. Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years. A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2020 202,246 $ 80.14 3.52 $ - Exercisable January 1, 2020 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Expired (35,741 ) Outstanding December 31, 2020 166,505 $ 85.81 3.14 $ - Exercisable December 31, 2020 166,536 $ 87.00 2.98 $ - Canceled - Granted - Exercised - Expired (25,383 ) Outstanding March 31, 2021 141,122 $ 99.08 3.42 $ - Exercisable March 31, 2021 135,934 $ 100.89 3.27 $ - The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on March 31, 2021, based on a valuation of the Company’s stock for that day. A summary of the Company’s non-vested options for the three-months ended March 31, 2021, and year ended December 31, 2020, are presented below: Non-vested as of January 1, 2020 10,138 Granted - Vested (4,169 ) Canceled - Non-vested as of December 31, 2020 5,969 Granted - Vested (781 ) Canceled - Non-vested as of March 31, 2021 5,188 Option valuation The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes valuation model and recognizes an expense ratably over the requisite service period. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected volatility is calculated based on the historical volatility of the Company. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period. During the three-months ended March 31, 2021, and the year ended December 31, 2020, no options were granted. Stock-based compensation expense The Company recognized stock-based compensation expense related to options during the: Three-months ended March 31 2021 2020 Amount Amount Service provider compensation $ 10,625 $ 44,375 Employee compensation 39,687 39,688 Total $ 50,312 $ 84,063 Option expiration During the three-months ended March 31, 2021, and the year ended December 31, 2020, options to purchase an aggregate of 25,383 and 35,741 shares of common stock expired. |
Warrants
Warrants | 3 Months Ended |
Mar. 31, 2021 | |
Warrants and Rights Note Disclosure [Abstract] | |
Warrants | NOTE 14 – WARRANTS The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2020 516,748 $ 24.60 1.86 $ - Exercisable January 1, 2020 516,748 $ 24.60 1.86 $ - Canceled - Granted 349,358 Exercised - Expired (85,171 ) Outstanding December 31, 2020 780,935 $ 15.47 3.53 $ - Exercisable December 31, 2020 780,935 $ 15.47 3.53 $ - Canceled - Granted 120,264 Exercised - Expired - Outstanding March 31, 2021 901,199 $ 13.96 3.70 $ 25,937 Exercisable March 31, 2021 900,849 $ 13.97 3.70 $ 25,153 Warrant valuation The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes valuation model. The range of fair value assumptions related to warrants issued were as follows for the: Three-months ended Year ended Dividend yield 0.0 % 0.0 % Risk-free rate 0.15% – 0.92 % 1.13% – 1.55 % Volatility 151% – 187 % 143% – 168 % Expected term 2.5 – 5 years 2 – 5 years The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected volatility is calculated based on the historical volatility of the Company. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. Convertible note warrants During the three-months ended March 31, 2021, warrants to purchase 85,000 shares of common stock at $5.00 per share were issued in connection with the issuance of convertible notes. During the year ended December 31, 2020, warrants to purchase 230,670 shares of common stock at $4.50 to $10.00 per share were issued in connection with the issuance of convertible notes. These warrants were immediately vested and expire in five years. The value of the warrants was recorded as a discount on the convertible notes in the aggregate amount of $110,450 and $295,854 during the three-months ended March 31, 2021, and the year ended December 31, 2020, respectively. Director warrant grants The Company granted its independent directors warrants as follows: Date of Grant Warrants Exercise Price March 31, 2020 12,756 $ 6.00 June 30, 2020 34,248 $ 2.25 September 30, 2020 25,952 $ 3.00 December 31, 2020 45,732 $ 1.70 March 31, 2021 34,564 $ 2.25 These warrants were immediately vested and expire in ten years. During the three-months ended March 31, 2021 and 2020, the Company recognized stock-based compensation expense related to these warrants in the aggregate amount of $75,000. Placement agent warrants On January 11, 2021, warrants to purchase 700 shares of common stock were issued to a registered broker-dealer engaged by the Company as placement agent for the preferred stock issuance. The exercise price for one half of the warrants is $0.01 per share and can only be exercised from and after 12 months from issuance. The exercise price for the other half of the warrants is $5.00 per share and can be exercised at any time. The warrants expire in 5 years. The value of the warrants was recorded as a stock issuance cost in the aggregate amount of $903. Warrant expiration During the three-months ended March 31, 2021, no warrants to purchase shares of common stock expired. During the year ended December 31, 2020, warrants to purchase an aggregate of 85,171 shares of common stock expired. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE 15 – INCOME TAXES The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. The effective tax rate for the three -months ended March 31, 2021 and 2020, differs from the statutory rate of 21% as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets. The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes Uncertain tax positions The Company is subject to taxation in the United States and three state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events. As of March 31, 2021, and December 31, 2020, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed. |
Basic and Diluted Net Loss Per
Basic and Diluted Net Loss Per Share | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Net Loss Per Share | NOTE 16 – BASIC AND DILUTED NET LOSS PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended March 31, 2021 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,382,118 ) 794,183 $ (1.74 ) Effect of dilutive securities—Common stock options, warrants, convertible notes, and preferred stock - - - Diluted loss per share $ (1,382,118 ) 794,183 $ (1.74 ) Three-months ended March 31, 2020 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,002,868 ) 700,879 $ (1.43 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: March 31, 2021 March 31, 2020 (Unaudited) (Unaudited) Common stock underlying convertible notes 688,147 443,410 Common stock underlying options 141,122 202,246 Common stock underlying warrants 901,199 447,036 Common stock underlying preferred stock 10,172 - Total common stock equivalents 1,740,640 1,092,692 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Leases | NOTE 17 – LEASES Office lease The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $9,255 and $8,989 for the three-months ended March 31, 2021 and 2020, respectively. Fleet lease In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases required monthly payments of $1,619 for three years. The Company terminated one lease in August of 2019, which reduced the monthly payments to $1,002. The Company terminated the remaining two leases in January 2021. Total lease expense under this agreement was $1,783 and $3,754 for the three-months ended March 31, 2021 and 2020, respectively. Right-of-use leased asset and liability As a result of the adoption of ASU No. 2016-02, Leases |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | NOTE 18 – SUBSEQUENT EVENTS The Company evaluated all material events through the date the financials were ready for issuance and identified the following for additional disclosure. Note payable On April 20, 2021, the Company received an Economic Injury Disaster Loan from the U.S. Small Business Administration in the amount of $500,000, which was funded on April 26, 2021. The loan accrues interest at the rate of 3.75% per annum. Installment payments, including principal and interest, of $2,505 per month, will begin eighteen (18) months from the date of issuance. The balance of principal and interest will be payable thirty (30) years from the date of issuance. The loan is secured by all tangible and intangible assets of the Company and personally guaranteed by the Company’s Chief Executive Officer as an individual. Convertible note payable On May 11, 2021, an amendment to the convertible note payable issued May 14, 2020, in the original principal amount of $500,000, extended the maturity date to June 11, 2021. As consideration for the extension, the Company paid an extension fee of $25,000 on May 12, 2021. All other terms remain unchanged. The amendment to this note was not considered a material modification under ASC 470-50-40, and as a result, is not considered an accounting extinguishment in the period the note was modified. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Unaudited Interim Financial Information | Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on April 15, 2021 (the “Annual Report”). |
Revenue from Contracts with Customers | Revenue from contracts with customers Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2021 March 31, 2020 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 104,574 $ 142,813 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale. |
Notes Payable | Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, debt issuance costs, and modifications. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt ● Debt modifications. Debt Modifications and Extinguishments |
Stock Issuance Costs | Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs |
Other Significant Accounting Policies | Other significant accounting policies There have been no other material changes to our significant accounting policies during the three-months ended March 31, 2021, as compared to the significant accounting policies described in our Annual Report. |
Recently Issued Accounting Pronouncements | Recently issued accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on its condensed consolidated financial statements. |
Reclassifications | Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Revenues Disaggregated by Revenue Source and Geographical Location | The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2021 March 31, 2020 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 104,574 $ 142,813 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | Inventories consist of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Raw materials $ 759,400 $ 759,400 Finished goods 203,459 234,919 Total inventories $ 962,859 $ 994,319 |
Intangible Assets, Net (Tables)
Intangible Assets, Net (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets, Net | Intangible assets, net, consists of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Patents $ 499,106 $ 499,106 Less accumulated amortization (265,060 ) (256,742 ) 234,046 242,364 Patents pending 56,179 60,047 Total intangible assets, net $ 290,225 $ 302,411 |
Related Party Notes Payable (Ta
Related Party Notes Payable (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Related Party Notes Payable | Related party notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note 500,000 500,000 Promissory note. - - Promissory note. 94,000 94,000 Promissory note. 100,000 100,000 Total related party notes payable 1,769,000 1,769,000 Less current portion (1,769,000 ) (769,000 ) Long term related party notes payable $ - $ 1,000,000 |
Related Party Convertible Not_2
Related Party Convertible Notes Payable (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Related Party Convertible Notes Payable | Related party convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-02. $ 815,217 $ 815,217 Convertible note 2019-07. 217,391 217,391 March 31, 2021 (Unaudited) December 31, 2020 Officer convertible note. 100,000 100,000 Convertible note 2020-11. 271,739 271,739 Convertible note 2020-16. - - Convertible note 2021-02. 100,000 - Convertible note 2021-03. 150,000 - Related party convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Total related party convertible notes payable 1,654,347 1,404,347 Less original issue discounts (104,347 ) (104,347 ) Related party convertible notes payable, net 1,550,000 1,300,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (448,710 ) (386,310 ) Plus amortization of discounts 461,905 420,606 Total related party convertible notes payable, net $ 1,563,195 $ 1,334,296 |
Convertible Notes Payable (Tabl
Convertible Notes Payable (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Convertible Notes Payable | Convertible notes payable consisted of the following as of: March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-01. $ - $ - Convertible note 2019-03. 108,696 108,696 Convertible note 2019-04. 54,348 54,348 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-05. 27,174 27,174 Convertible note 2019-06. 27,174 27,174 Convertible note 2019-08. 108,696 108,696 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2019-09. 27,174 27,174 Convertible note 2019-10. 16,304 16,304 Convertible note 2020-01. 10,870 10,870 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-02. - 133,272 Convertible note 2020-03. 52,632 52,632 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-04. - - Convertible note 2020-05. 260,000 260,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-06. 500,000 500,000 Convertible note 2020-07. 100,000 100,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-08. 25,000 25,000 Convertible note 2020-09. 100,000 100,000 Convertible note 2020-10. 15,000 15,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-12. 25,000 25,000 Convertible note 2020-13. 108,696 108,696 Convertible note 2020-14. 60,000 60,000 March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2020-15. 20,000 20,000 Convertible note 2020-17. 55,556 55,556 Convertible note 2021-01. 55,556 - March 31, 2021 (Unaudited) December 31, 2020 Convertible note 2021-04. 100,000 - Total convertible notes payable 1,857,876 1,835,592 Less original issue discounts (112,876 ) (107,320 ) Convertible notes payable, net 1,745,000 1,728,272 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants (1,162,604 ) (1,062,054 ) Plus amortization of discounts 1,058,223 802,313 Total convertible notes payable, net $ 1,640,619 $ 1,468,531 |
Derivative Financial Instrume_2
Derivative Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Fair Value Assumptions Related to Option Issued | The range of fair value assumptions used for derivative financial instruments were as follows for the: Three-months ended Year ended December 31, 2020 Dividend yield 0 % 0 % Risk-free rate 0.07 % 0.10% - 1.43 % Volatility 158 % 147% - 190 % Expected term 1 year 1 year The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 Change in Fair Value December 31, 2020 $ - $ - $ 235,165 $ (222,707 ) March 31, 2021 $ - $ - $ 412,163 $ 176,998 |
Schedule of Recognized Derivative Liabilities | The Company recognized derivative liabilities as follows: Derivative liabilities as of January 1, 2020 $ 827,314 Valuation upon issuance 433,672 Revaluation upon modification (344,137 ) Change in fair value (222,707 ) Elimination upon extinguishment (458,977 ) Derivative liabilities as of December 31, 2020 235,165 Change in fair value 176,998 Derivative liabilities as of March 31, 2021 $ 412,163 |
Stock Option Plans (Tables)
Stock Option Plans (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock Option Activity | A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2020 202,246 $ 80.14 3.52 $ - Exercisable January 1, 2020 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Expired (35,741 ) Outstanding December 31, 2020 166,505 $ 85.81 3.14 $ - Exercisable December 31, 2020 166,536 $ 87.00 2.98 $ - Canceled - Granted - Exercised - Expired (25,383 ) Outstanding March 31, 2021 141,122 $ 99.08 3.42 $ - Exercisable March 31, 2021 135,934 $ 100.89 3.27 $ - |
Schedule of Non-vested Shares Granted Under Stock Option Plan | A summary of the Company’s non-vested options for the three-months ended March 31, 2021, and year ended December 31, 2020, are presented below: Non-vested as of January 1, 2020 10,138 Granted - Vested (4,169 ) Canceled - Non-vested as of December 31, 2020 5,969 Granted - Vested (781 ) Canceled - Non-vested as of March 31, 2021 5,188 |
Schedule of Recognized Stock Based Compensation Expense | The Company recognized stock-based compensation expense related to options during the: Three-months ended March 31 2021 2020 Amount Amount Service provider compensation $ 10,625 $ 44,375 Employee compensation 39,687 39,688 Total $ 50,312 $ 84,063 |
Warrants (Tables)
Warrants (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Warrants and Rights Note Disclosure [Abstract] | |
Schedule of Stock Warrants Activity | The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2020 516,748 $ 24.60 1.86 $ - Exercisable January 1, 2020 516,748 $ 24.60 1.86 $ - Canceled - Granted 349,358 Exercised - Expired (85,171 ) Outstanding December 31, 2020 780,935 $ 15.47 3.53 $ - Exercisable December 31, 2020 780,935 $ 15.47 3.53 $ - Canceled - Granted 120,264 Exercised - Expired - Outstanding March 31, 2021 901,199 $ 13.96 3.70 $ 25,937 Exercisable March 31, 2021 900,849 $ 13.97 3.70 $ 25,153 |
Schedule of Fair Value of Warrant Valuations | The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes valuation model. The range of fair value assumptions related to warrants issued were as follows for the: Three-months ended Year ended Dividend yield 0.0 % 0.0 % Risk-free rate 0.15% – 0.92 % 1.13% – 1.55 % Volatility 151% – 187 % 143% – 168 % Expected term 2.5 – 5 years 2 – 5 years |
Schedule of Independent Directors Warrants | The Company granted its independent directors warrants as follows: Date of Grant Warrants Exercise Price March 31, 2020 12,756 $ 6.00 June 30, 2020 34,248 $ 2.25 September 30, 2020 25,952 $ 3.00 December 31, 2020 45,732 $ 1.70 March 31, 2021 34,564 $ 2.25 |
Basic and Diluted Net Loss Pe_2
Basic and Diluted Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss Per Share | The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended March 31, 2021 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,382,118 ) 794,183 $ (1.74 ) Effect of dilutive securities—Common stock options, warrants, convertible notes, and preferred stock - - - Diluted loss per share $ (1,382,118 ) 794,183 $ (1.74 ) Three-months ended March 31, 2020 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,002,868 ) 700,879 $ (1.43 ) |
Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share | The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: March 31, 2021 March 31, 2020 (Unaudited) (Unaudited) Common stock underlying convertible notes 688,147 443,410 Common stock underlying options 141,122 202,246 Common stock underlying warrants 901,199 447,036 Common stock underlying preferred stock 10,172 - Total common stock equivalents 1,740,640 1,092,692 |
Company Background (Details Nar
Company Background (Details Narrative) - USD ($) | Jan. 11, 2021 | Aug. 14, 2019 | Apr. 28, 2021 | Feb. 28, 2021 | Apr. 30, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 |
Net losses | $ (1,382,118) | $ (1,002,868) | ||||||
Accumulated deficit | (73,473,980) | $ (72,091,862) | ||||||
Proceeds from issuance of debt securities | 50,000 | |||||||
Proceeds from sale of preferred stock | 611,359 | |||||||
Proceeds from issuance of common stock and warrants | $ 15,000,000 | |||||||
Aggregate amount of shares issued | 50,000 | |||||||
Proceeds from the issuance of notes payable | $ 211,359 | |||||||
Economic Injury Disaster Loan [Member] | ||||||||
Proceeds from the issuance of notes payable | $ 500,000 | |||||||
Paycheck Protection Program [Member] | ||||||||
Proceeds from the issuance of notes payable | $ 211,359 | $ 211,300 | ||||||
Preferred Stock [Member] | Private Placement [Member] | ||||||||
Proceeds from sale of preferred stock | $ 50,000 | |||||||
Preferred Stock [Member] | Private Placement [Member] | Maximum [Member] | ||||||||
Aggregate amount of shares issued | $ 10,000,000 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Accounting Policies [Abstract] | ||
Payment of stock issuance costs | $ (76,460) |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source and Geographical Location (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Total revenue | $ 104,574 | $ 142,813 |
United States [Member] | ||
Total revenue | $ 104,574 | $ 142,813 |
Inventories (Details Narrative)
Inventories (Details Narrative) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Inventory, finished goods | $ 191,721 | $ 227,597 |
Inventories - Schedule of Inven
Inventories - Schedule of Inventories (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 759,400 | $ 759,400 |
Finished goods | 203,459 | 234,919 |
Total inventories | $ 962,859 | $ 994,319 |
Intangible Assets, Net (Details
Intangible Assets, Net (Details Narrative) | 3 Months Ended | |
Mar. 31, 2021USD ($)Vehicle | Mar. 31, 2020USD ($) | |
Patent, amortization period | 15 years | |
Amortization expense | $ | $ 8,318 | $ 8,733 |
Loss from abandoned patent | $ | $ 4,690 | |
Patents, units | 28 | |
Patents expiration date | Patents will expire between 2023 and 2028 | |
Number of patent application pending | 3 | |
Number of patent application pending, description | The Company also has three additional patents pending that if issued would extend patent coverage in the U.S. and outside the U.S. to 2039-2041. | |
United States [Member] | ||
Patents, units | 13 | |
Outside the U.S. [Member] | ||
Patents, units | 15 |
Intangible Assets, Net - Schedu
Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Patents | $ 499,106 | $ 499,106 |
Less accumulated amortization | (265,060) | (256,742) |
Patents, Total | 234,046 | 242,364 |
Patents pending | 56,179 | 60,047 |
Total intangible assets, net | $ 290,225 | $ 302,411 |
Accrued Separation Costs (Detai
Accrued Separation Costs (Details Narrative) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 | Aug. 09, 2016 |
Accrued separation costs outstanding | $ 80,635 | ||
Accrued separation costs, current portion | $ 12,000 | $ 12,000 | |
Separation Agreement [Member] | |||
Accrued compensation expenses | $ 118,635 |
Related Party Notes Payable (De
Related Party Notes Payable (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Interest charges | $ 48,175 | $ 45,593 |
Related Party Notes Payable [Member] | ||
Unpaid interest | $ 165,001 | $ 63,143 |
Related Party Notes Payable - S
Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Total related party notes payable | $ 1,769,000 | $ 1,769,000 |
Less current portion | (1,769,000) | (769,000) |
Long term notes payable | 1,000,000 | |
Inventory Financing [Member] | ||
Total related party notes payable | 1,000,000 | 1,000,000 |
Officer Loan [Member] | ||
Total related party notes payable | 75,000 | 75,000 |
Promissory Note [Member] | ||
Total related party notes payable | 500,000 | 500,000 |
Promissory Note [Member] | ||
Total related party notes payable | ||
Promissory Note [Member] | ||
Total related party notes payable | 94,000 | 94,000 |
Promissory Note [Member] | ||
Total related party notes payable | $ 100,000 | $ 100,000 |
Related Party Notes Payable -_2
Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) (Parenthetical) - USD ($) | Dec. 30, 2020 | Nov. 06, 2020 | Jun. 29, 2020 | Jun. 26, 2019 | May 20, 2019 | Jan. 11, 2019 | Jul. 14, 2020 | Jul. 10, 2019 |
Debt instrument, interest rate | 12.00% | |||||||
Inventory Financing [Member] | ||||||||
Line of credit | $ 1,000,000 | |||||||
Line of credit facility, interest rate | 12.00% | |||||||
Inventory Financing [Member] | Minimum [Member] | ||||||||
Ownership percentage | 5.00% | |||||||
Officer Loan [Member] | ||||||||
Debt instrument description | The Company borrowed $75,000 from the Chief Executive Officer of the Company. This note accrues interest at the rate of 4.5% per annum, payable at maturity, is unsecured, and was originally due August 26, 2019, but the maturity date was extended to June 30, 2021. | |||||||
Officer Loan [Member] | Chief Executive Officer [Member] | ||||||||
Loan borrowed | $ 75,000 | |||||||
Debt instrument, interest rate | 4.50% | |||||||
Promissory Note [Member] | ||||||||
Loan borrowed | $ 100,000 | |||||||
Debt instrument description | This note accrues interest at the rate of 12% per annum, payable at maturity, is unsecured, and was originally due August 20, 2019, but the maturity date was extended to June 30, 2021. | |||||||
Debt instrument, interest rate | 12.00% | |||||||
Note payable | $ 400,000 | |||||||
Promissory Note [Member] | Minimum [Member] | ||||||||
Ownership percentage | 5.00% | |||||||
Promissory Note [Member] | ||||||||
Ownership percentage | 5.00% | |||||||
Debt instrument description | This note accrued interest at the rate of 12% per annum, payable at maturity, was unsecured, and was originally due September 30, 2020, but the maturity date was extended to October 15, 2020. This note was fully repaid on October 8, 2020. | |||||||
Debt instrument, interest rate | 12.00% | |||||||
Note payable | $ 25,000 | |||||||
Promissory Note [Member] | ||||||||
Ownership percentage | 5.00% | |||||||
Debt instrument description | This note accrued an issuance fee of $4,000 and a one-time fixed interest charge upon issuance of $2,000, payable at maturity, is unsecured, and was originally due December 6, 2020, but the maturity date was extended to June 30, 2021. | |||||||
Note payable | $ 94,000 | |||||||
Issuance fee | 4,000 | |||||||
One-time fixed interest charges | $ 2,000 | |||||||
Promissory Note [Member] | ||||||||
Ownership percentage | 5.00% | |||||||
Debt instrument description | This note accrues interest at the rate of 12% per annum, is unsecured, and was originally due March 30, 2021, but the maturity date was extended to June 30, 2021. Interest was originally payable monthly but was amended on January 1, 2021, to be payable at maturity. | |||||||
Debt instrument, interest rate | 12.00% | |||||||
Note payable | $ 100,000 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) - USD ($) | May 11, 2021 | Feb. 08, 2021 | Jul. 14, 2020 | Apr. 22, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Apr. 30, 2021 |
Note payable | $ 25,000 | |||||||
Debt instrument, interest rate | 12.00% | |||||||
Debt instrument, maturity date | Jul. 31, 2020 | |||||||
Interest charges | $ 48,175 | $ 45,593 | ||||||
Subsequent Event [Member] | ||||||||
Debt instrument, maturity date | Jun. 11, 2021 | |||||||
Paycheck Protection Program [Member] | Lender [Member] | ||||||||
Proceeds from loan | $ 211,359 | $ 211,300 | ||||||
Note payable, description | The Company received a Second Draw Paycheck Protection Program ("PPP") loan for $211,359, which was funded on February 8, 2021. Under the terms of the program, the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures five (5) years from issuance and accrues interest at 1% per annum with principal and interest payments deferred until the SBA remits the Company's loan forgiveness amount to the lender. If the Company does not apply for loan forgiveness, payments will be deferred 10 months after the end of the covered period for loan forgiveness (24 weeks following loan disbursement). Management believes the loan will be eligible for forgiveness in accordance with the terms of the program | The Company received a Paycheck Protection Program ("PPP") loan under the U.S. Small Business Administration (the "SBA") for $211,300, which was funded on April 22, 2020. Under the terms of the program, up to 100% of the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures two (2) years from issuance and accrues interest at 1% per annum with principal and interest payments deferred until the SBA remits the Company's loan forgiveness amount to the lender. The Company applied for forgiveness in May 2021. Management believes the loan is eligible for forgiveness in accordance with the terms of the program. If the loan amount is not forgiven in full, the Company expects to repay any unforgiven amount within one year of March 31, 2021, so the loan amount is recorded as a current liability. | ||||||
Note Payable [Member] | ||||||||
Interest charges | 822 | 0 | ||||||
Accrued and unpayable | $ 2,289 | $ 0 | ||||||
Note Payable [Member] | Economic Injury Disaster Loan [Member] | ||||||||
Proceeds from advance | $ 10,000 | |||||||
Note Payable [Member] | Economic Injury Disaster Loan [Member] | Subsequent Event [Member] | ||||||||
Note payable | $ 500,000 |
Related Party Convertible Not_3
Related Party Convertible Notes Payable (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | |||
Sep. 30, 2020 | Feb. 29, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Original issue discount | $ 104,347 | $ 104,347 | |||
Gain on convertible notes | $ 40,133 | $ 95,888 | 3,272 | $ 354,791 | |
Interest charges incurred | 48,175 | 45,593 | |||
Related Party Convertible Note Payable [Member] | |||||
Original issue discount | 553,057 | ||||
Interest expense | 41,299 | 112,446 | |||
Accumulated amortization | 461,905 | ||||
Gain on convertible notes | $ 258,903 | ||||
Interest charges incurred | 31,352 | 24,020 | |||
Interest accrued and unpayable | $ 41,376 | $ 8,183 | |||
Related Party Convertible Note Payable [Member] | Maximum [Member] | |||||
Related party convertible notes payable, term | 1 year |
Related Party Convertible Not_4
Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 17, 2020 | Feb. 25, 2020 | Oct. 16, 2019 | Jul. 19, 2019 |
Total related party convertible notes payable | $ 1,654,347 | $ 1,404,347 | ||||
Less original issue discounts | (104,347) | (104,347) | ||||
Related party convertible notes payable, net | 1,550,000 | 1,300,000 | ||||
Less discounts for conversion rights, beneficial conversion features, and detachable warrants | (448,710) | (386,310) | ||||
Plus amortization of discounts | 461,905 | 420,606 | ||||
Total related party convertible notes payable, net | 1,563,195 | 1,334,296 | ||||
Convertible Note 2019 - 02 [Member] | ||||||
Total related party convertible notes payable | 815,217 | 815,217 | ||||
Less original issue discounts | $ (65,217) | |||||
Convertible Note 2019 - 07 [Member] | ||||||
Total related party convertible notes payable | 217,391 | 217,391 | ||||
Less original issue discounts | $ (17,391) | |||||
Officers Convertible Note [Member] | ||||||
Total related party convertible notes payable | 100,000 | 100,000 | ||||
Convertible Note 2020 - 11 [Member] | ||||||
Total related party convertible notes payable | 271,739 | 271,739 | ||||
Less original issue discounts | $ (21,739) | |||||
Convertible Note 2020 - 16 [Member] | ||||||
Total related party convertible notes payable | ||||||
Convertible Note 2021 - 02 [Member] | ||||||
Total related party convertible notes payable | 100,000 | |||||
Convertible Note 2021-03 [Member] | ||||||
Total related party convertible notes payable | $ 150,000 | |||||
Less original issue discounts | $ (2,632) |
Related Party Convertible Not_5
Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) | Mar. 08, 2021USD ($)$ / sharesshares | Jan. 28, 2021USD ($)$ / sharesshares | Dec. 17, 2020USD ($)shares | Sep. 17, 2020USD ($)$ / sharesshares | Jul. 14, 2020 | Feb. 25, 2020USD ($)$ / sharesshares | Nov. 15, 2019USD ($)$ / shares | Oct. 16, 2019USD ($)$ / sharesshares | Jul. 19, 2019USD ($)$ / sharesshares | Mar. 31, 2021USD ($)$ / shares | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($)$ / shares |
Original issue discount | $ 104,347 | $ 104,347 | ||||||||||
Debt instrument, interest rate | 12.00% | |||||||||||
Debt instrument, maturity date | Jul. 31, 2020 | |||||||||||
Convertible Note 2019 - 02 [Member] | ||||||||||||
Convertible notes payable issued | $ 815,217 | |||||||||||
Original issue discount | 65,217 | |||||||||||
Exchange of convertible notes payable | $ 750,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||
Debt instrument, conversion price | $ / shares | $ 24 | $ 4.27 | $ 4.27 | |||||||||
Debt instrument, discount offering price percentage | 0.25 | |||||||||||
Warrants price per share | $ / shares | 4.27 | $ 4.27 | ||||||||||
Debt instrument beneficial conversion feature | $ 234,300 | $ 234,300 | ||||||||||
Convertible Note 2019 - 02 [Member] | Detachable Warrant [Member] | ||||||||||||
Warrants to purchase common stock | shares | 7,500 | |||||||||||
Warrants price per share | $ / shares | $ 24 | |||||||||||
Convertible Note 2019 - 02 [Member] | Minimum [Member] | ||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||
Convertible Note 2019 - 02 [Member] | Extended Maturity [Member] | ||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||
Convertible Note 2019 - 07 [Member] | ||||||||||||
Convertible notes payable issued | $ 217,391 | |||||||||||
Original issue discount | 17,391 | |||||||||||
Exchange of convertible notes payable | $ 200,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||
Debt instrument, conversion price | $ / shares | $ 24 | 4.27 | $ 4.27 | |||||||||
Debt instrument, discount offering price percentage | 0.25 | |||||||||||
Warrants price per share | $ / shares | $ 4.27 | $ 4.27 | ||||||||||
Debt instrument beneficial conversion feature | $ 63,060 | $ 63,060 | ||||||||||
Convertible Note 2019 - 07 [Member] | Detachable Warrant [Member] | ||||||||||||
Warrants to purchase common stock | shares | 2,000 | |||||||||||
Warrants price per share | $ / shares | $ 24 | |||||||||||
Convertible Note 2019 - 07 [Member] | Minimum [Member] | ||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||
Convertible Note 2019 - 07 [Member] | Extended Maturity [Member] | ||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||
Officer Convertible Note [Member] | ||||||||||||
Convertible notes payable issued | $ 100,000 | |||||||||||
Debt instrument, interest rate | 14.00% | |||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||
Debt instrument, conversion price | $ / shares | $ 20 | |||||||||||
Officer Convertible Note [Member] | Extended Maturity [Member] | ||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||
Convertible Note 2020 - 11 [Member] | ||||||||||||
Convertible notes payable issued | $ 217,391 | |||||||||||
Original issue discount | 21,739 | |||||||||||
Exchange of convertible notes payable | $ 250,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||
Debt instrument, conversion price | $ / shares | $ 4.50 | |||||||||||
Debt instrument, discount offering price percentage | 0.25 | |||||||||||
Debt instrument beneficial conversion feature | $ 88,950 | |||||||||||
Convertible Note 2020 - 11 [Member] | Detachable Warrant [Member] | ||||||||||||
Warrants to purchase common stock | shares | 13,333 | |||||||||||
Warrants price per share | $ / shares | $ 4.50 | |||||||||||
Convertible Note 2020 - 11 [Member] | Minimum [Member] | ||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||
Convertible Note 2020 - 16 [Member] | ||||||||||||
Convertible notes payable issued | $ 90,000 | |||||||||||
Debt instrument, interest rate | 4.00% | |||||||||||
Debt instrument, maturity date | Dec. 31, 2021 | |||||||||||
Debt instrument converted into shares of common stock | shares | 18,000 | |||||||||||
Convertible Note 2021 - 02 [Member] | Lender [Member] | ||||||||||||
Convertible notes payable issued | $ 100,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Debt instrument, maturity date | Dec. 31, 2021 | |||||||||||
Debt instrument, conversion price | $ / shares | $ 5 | |||||||||||
Convertible notes, maturity description | If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months | |||||||||||
Convertible Note 2021 - 02 [Member] | Detachable Warrant [Member] | Lender [Member] | ||||||||||||
Original issue discount | $ 22,200 | |||||||||||
Warrants to purchase common stock | shares | 20,000 | |||||||||||
Warrants price per share | $ / shares | $ 5 | |||||||||||
Warrant exercisable term | 5 years | |||||||||||
Convertible Note 2021-03 [Member] | ||||||||||||
Convertible notes payable issued | $ 150,000 | $ 52,632 | ||||||||||
Original issue discount | 2,632 | |||||||||||
Exchange of convertible notes payable | $ 50,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Debt instrument, maturity date | Mar. 8, 2022 | Jun. 30, 2020 | ||||||||||
Debt instrument, conversion price | $ / shares | $ 5 | $ 7.50 | ||||||||||
Convertible notes, maturity description | The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. | |||||||||||
Ownership percentage | 5.00% | |||||||||||
Convertible Note 2021-03 [Member] | Detachable Warrant [Member] | ||||||||||||
Warrants to purchase common stock | shares | 500 | |||||||||||
Warrants price per share | $ / shares | $ 7.50 | |||||||||||
Convertible Note 2021-03 [Member] | Detachable Warrant Two [Member] | ||||||||||||
Original issue discount | $ 40,200 | |||||||||||
Warrants to purchase common stock | shares | 30,000 | |||||||||||
Warrants price per share | $ / shares | $ 5 | |||||||||||
Warrant exercisable term | 5 years | |||||||||||
Convertible Note 2021-03 [Member] | Minimum [Member] | ||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||
Convertible Note 2021-03 [Member] | Extended Maturity [Member] | ||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | ||||
Sep. 30, 2020 | Feb. 29, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | |
Original issue discount | $ 322,209 | $ 297,656 | ||||
Gain on convertible notes | $ 40,133 | $ 95,888 | 3,272 | 354,791 | ||
Interest charges incurred | 48,175 | 45,593 | ||||
Convertible Note Payable [Member] | ||||||
Original issue discount | 1,275,480 | |||||
Interest expense | 280,910 | 185,210 | ||||
Accumulated amortization | $ 1,058,223 | |||||
Interest charges incurred | $ 39,452 | $ 39,426 | ||||
Interest accrued and unpayable | $ 102,310 | $ 31,370 |
Convertible Notes Payable - Sch
Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Total convertible notes payable | $ 1,654,347 | $ 1,404,347 |
Plus amortization of discounts | (461,905) | (420,606) |
Convertible Note 2019 - 01 [Member] | ||
Total convertible notes payable | ||
Convertible Note 2019 - 03 [Member] | ||
Total convertible notes payable | 108,696 | 108,696 |
Convertible Note 2019 - 04 [Member] | ||
Total convertible notes payable | 54,348 | 54,348 |
Convertible Note 2019 - 05 [Member] | ||
Total convertible notes payable | 27,174 | 27,174 |
Convertible Note 2019 - 06 [Member] | ||
Total convertible notes payable | 27,174 | 27,174 |
Convertible Note 2019 - 08 [Member] | ||
Total convertible notes payable | 108,696 | 108,696 |
Convertible Note 2019 - 09 [Member] | ||
Total convertible notes payable | 27,174 | 27,174 |
Convertible Note 2019 - 10 [Member] | ||
Total convertible notes payable | 16,304 | 16,304 |
Convertible Note 2020 - 01 [Member] | ||
Total convertible notes payable | 10,870 | 10,870 |
Convertible Note 2020 - 02 [Member] | ||
Total convertible notes payable | 133,272 | |
Convertible Note 2020 - 03 [Member] | ||
Total convertible notes payable | 52,632 | 52,632 |
Convertible Note 2020 - 04 [Member] | ||
Total convertible notes payable | ||
Convertible Note 2020 - 05 [Member] | ||
Total convertible notes payable | 260,000 | 260,000 |
Convertible Note 2020 - 06 [Member] | ||
Total convertible notes payable | 500,000 | 500,000 |
Convertible Note 2020 - 07 [Member] | ||
Total convertible notes payable | 100,000 | 100,000 |
Convertible Note 2020 - 08 [Member] | ||
Total convertible notes payable | 25,000 | 25,000 |
Convertible Note 2020 - 09 [Member] | ||
Total convertible notes payable | 100,000 | 100,000 |
Convertible Note 2020 - 10 [Member] | ||
Total convertible notes payable | 15,000 | 15,000 |
Convertible Note 2020 - 12 [Member] | ||
Total convertible notes payable | 25,000 | 25,000 |
Convertible Note 2020 - 13 [Member] | ||
Total convertible notes payable | 108,696 | 108,696 |
Convertible Note 2020 - 14 [Member] | ||
Total convertible notes payable | 60,000 | 60,000 |
Convertible Note 2020 - 15 [Member] | ||
Total convertible notes payable | 20,000 | 20,000 |
Convertible Note 2020 - 17 [Member] | ||
Total convertible notes payable | 55,556 | 55,556 |
Convertible Note 2021-01 [Member] | ||
Total convertible notes payable | 55,556 | |
Convertible note 2021-04 [Member] | ||
Total convertible notes payable | 100,000 | |
Convertible Note 2021-04 [Member] | ||
Total convertible notes payable | 1,857,876 | |
Less original issue discounts | (112,876) | |
Convertible notes payable, net | 1,745,000 | |
Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants | (1,162,604) | |
Plus amortization of discounts | 1,058,223 | |
Total convertible notes payable, net | $ 1,640,619 | |
Convertible Note Payable [Member] | ||
Total convertible notes payable | 1,835,592 | |
Less original issue discounts | (107,320) | |
Convertible notes payable, net | 1,728,272 | |
Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants | (1,062,054) | |
Plus amortization of discounts | 802,313 | |
Total convertible notes payable, net | $ 1,468,531 |
Convertible Notes Payable - S_2
Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($) | May 10, 2021 | Apr. 30, 2021 | Apr. 22, 2021 | Apr. 14, 2021 | Mar. 30, 2021 | Mar. 26, 2021 | Mar. 12, 2021 | Mar. 08, 2021 | Feb. 26, 2021 | Feb. 22, 2021 | Feb. 12, 2021 | Jan. 28, 2021 | Jan. 27, 2021 | Dec. 28, 2020 | Dec. 11, 2020 | Dec. 01, 2020 | Nov. 13, 2020 | Nov. 10, 2020 | Nov. 09, 2020 | Oct. 08, 2020 | Sep. 28, 2020 | Sep. 22, 2020 | Sep. 18, 2020 | Sep. 08, 2020 | Aug. 07, 2020 | Jul. 30, 2020 | Jul. 21, 2020 | Jul. 14, 2020 | May 14, 2020 | May 12, 2020 | Mar. 16, 2020 | Feb. 25, 2020 | Jan. 21, 2020 | Jan. 06, 2020 | Nov. 08, 2019 | Oct. 29, 2019 | Oct. 23, 2019 | Oct. 10, 2019 | Oct. 03, 2019 | Sep. 25, 2019 | Sep. 04, 2019 | Apr. 18, 2019 | Mar. 31, 2021 | Mar. 29, 2021 | Feb. 02, 2021 | Dec. 31, 2020 | Aug. 10, 2020 | Mar. 17, 2020 |
Debt instrument, interest rate | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jul. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 104,347 | $ 104,347 | ||||||||||||||||||||||||||||||||||||||||||||||
Inventory | 962,859 | 994,319 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 01 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Dec. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument maturity date, description | Originally due December 31, 2019, but the maturity date was extended to March 31, 2020. | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Adjusted exercise price per share | $ 4.27 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 01 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 2,500 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 40 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 03 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 108,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 8,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 24 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 03 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 03 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 18,326 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 04 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 54,348 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 4,348 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 04 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 04 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 500 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 4,190 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 05 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 27,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 2,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 05 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 05 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 2,705 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 06 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 27,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 2,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 06 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 06 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 2,505 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 08 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 108,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 8,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 08 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 08 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 21,363 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 08 [Member] | Detachable Warrant One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 1,250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 30 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 08 [Member] | Detachable Warrant Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 1,250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 40 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 09 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 27,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 2,174 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 09 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 09 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 24 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 2,295 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 10 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 16,304 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 14 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 1,304 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 10 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2019 - 10 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 150 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 14 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 3,279 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 01 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 10,870 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 10 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 870 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 01 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 01 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 100 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 10 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 793 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 02 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 262,500 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.27 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 12,500 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Number of common stock shares issued | 6,250 | |||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued as commitment fee | 5,855 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 02 [Member] | Holder [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Inventory | $ 10,000 | $ 200,000 | $ 20,000 | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||
Accrued and unpaid interest | 32,003 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, principal payment | 129,228 | |||||||||||||||||||||||||||||||||||||||||||||||
Premium principal repayment | $ 38,769 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 02 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Feb. 28, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 02 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 110,247 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-03 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 150,000 | $ 52,632 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Mar. 8, 2022 | Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument maturity date, description | The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | $ 7.50 | ||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 2,632 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, discount offering price percentage | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-03 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-03 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-03 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 500 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 7.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 1,985 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-03 [Member] | Detachable Warrant Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 40,200 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 04 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Sep. 16, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument maturity date, description | This note was fully repaid as of May 14, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 230,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued as commitment fee | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance cost | $ 27,777 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, description | Fully repaid within 6 months of issuance | |||||||||||||||||||||||||||||||||||||||||||||||
Legal expenses | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 04 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | 343,854 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 05 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Sep. 16, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 230,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Number of common stock shares issued | 27,777 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued as commitment fee | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Legal expenses | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 05 [Member] | Increased Principal as a Consideration for Extension [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 05 [Member] | Amount Paid as Consideration for Extension [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | $ 7,500 | $ 7,500 | $ 7,500 | $ 7,500 | $ 7,500 | $ 7,500 | ||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 05 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | May 25, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 05 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 343,854 | $ 368,854 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 06 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | May 14, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 9.75 | $ 4.50 | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||
Additional discount on convertible note | $ 342,658 | $ 280,158 | ||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 40,000 | $ 342,658 | $ 280,158 | |||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | 460,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Legal expenses | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 06 [Member] | Amount Paid as Consideration for Extension [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | $ 25,000 | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 06 [Member] | Shares issued as Commitment Fee [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of common stock shares issued | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 06 [Member] | Amount Paid as Additional Consideration for Extension [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | $ 25,000 | $ 12,500 | $ 12,500 | $ 12,500 | $ 12,500 | $ 12,500 | $ 12,500 | |||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 06 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 11, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 07 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, discount offering price percentage | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 07 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 07 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 7.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 105,800 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 07 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 10 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 08 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Sep. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 24 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 08 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 08 [Member] | Extended Maturity [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 08 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 250 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 953 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 09 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jul. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 24 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 09 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 7.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 106,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 09 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 10 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 10 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 10 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 7.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 5,300 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 12 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 12 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 5,555 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 11,499 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 13 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 108,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 8,696 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 13 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 24,155 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 50,001 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 14 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 14 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 13,333 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 27,599 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 15 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 15 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 4,444 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 4.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 9,199 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 17 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 55,556 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 5,556 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2020 - 17 [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 14,250 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-01 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 55,556 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 5,556 | |||||||||||||||||||||||||||||||||||||||||||||||
Exchange of convertible notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-01 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 16,650 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-04 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable issued | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Mar. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, conversion price | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, amortized period | 36 months | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note 2021-04 [Member] | Detachable Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common stock | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants price per share | $ 5 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants recognition | $ 31,400 |
Derivative Financial Instrume_3
Derivative Financial Instruments - Schedule of Fair Value Assumptions Related to Option Issued (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Derivative liabilities | $ 412,163 | $ 235,165 | $ 827,314 |
Convertible Note Payable [Member] | |||
Derivative liabilities | 176,998 | (222,707) | |
Convertible Note Payable [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Derivative liabilities | |||
Convertible Note Payable [Member] | Fair Value, Inputs, Level 2 [Member] | |||
Derivative liabilities | |||
Convertible Note Payable [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Derivative liabilities | $ 412,163 | $ 235,165 | |
Convertible Note Payable [Member] | Expected Dividend Yield [Member] | |||
Derivative liabilities, measurement input | 0 | 0 | |
Convertible Note Payable [Member] | Risk Free Interest Rate [Member] | |||
Derivative liabilities, measurement input | 0.07 | ||
Convertible Note Payable [Member] | Risk Free Interest Rate [Member] | Minimum [Member] | |||
Derivative liabilities, measurement input | 0.10 | ||
Convertible Note Payable [Member] | Risk Free Interest Rate [Member] | Maximum [Member] | |||
Derivative liabilities, measurement input | 1.43 | ||
Convertible Note Payable [Member] | Volatility [Member] | |||
Derivative liabilities, measurement input | 158 | ||
Convertible Note Payable [Member] | Volatility [Member] | Minimum [Member] | |||
Derivative liabilities, measurement input | 147 | ||
Convertible Note Payable [Member] | Volatility [Member] | Maximum [Member] | |||
Derivative liabilities, measurement input | 190 | ||
Convertible Note Payable [Member] | Expected Term [Member] | |||
Derivative liabilities, expected term | 1 year | 1 year |
Derivative Financial Instrume_4
Derivative Financial Instruments - Schedule of Recognized Derivative Liabilities (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
Derivative liabilities as of beginning | $ 235,165 | $ 827,314 |
Valuation upon issuance | 433,672 | |
Revaluation upon modification | (344,137) | |
Change in fair value | 176,998 | (222,707) |
Elimination upon extinguishment | (458,977) | |
Derivative liabilities as of ending | $ 412,163 | $ 235,165 |
Stockholders' Deficit (Details
Stockholders' Deficit (Details Narrative) - USD ($) | Jan. 11, 2021 | Dec. 17, 2020 | Jan. 15, 2020 | Mar. 31, 2021 | Dec. 31, 2020 |
Aggregate purchase price of shares | $ 50,000 | ||||
Reverse stock split | 200-for-1 reverse stock split | ||||
Common stock, shares outstanding | 802,516 | 794,183 | |||
Preferred stock, shares outstanding | 2,000 | 0 | |||
Restricted Common Stock [Member] | |||||
Debt conversion of shares | 18,000 | ||||
Debt conversion of amount | $ 90,000 | ||||
Series A Preferred Stock [Member] | |||||
Stock issued during period shares | 2,000 | 2,000 | |||
Aggregate purchase price of shares | $ 50,000 | $ 2 |
Stock Grants (Details Narrative
Stock Grants (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Number of shares granted during period | |||
Directors [Member] | |||
Recognized of grants | $ 18,750 | $ 18,750 | |
Holder [Member] | |||
Consideration for commitment fees, shares | 27,777 | ||
Issuance of debt cancelled shares | 27,777 | ||
Extension fees | $ 6,250 | ||
Restricted Common Stock [Member] | Directors [Member] | |||
Number of shares granted during period | 8,333 | 3,125 | |
Restricted Common Stock [Member] | Consultant [Member] | |||
Number of shares granted during period | 28,737 | ||
Restricted Common Stock [Member] | Holder [Member] | |||
Stock issued during period convertible note | 81,409 |
Stock Option Plans (Details Nar
Stock Option Plans (Details Narrative) - shares | Dec. 04, 2018 | Feb. 07, 2014 | Mar. 31, 2021 | Dec. 31, 2020 | Jan. 02, 2021 | Jan. 02, 2020 | Apr. 16, 2015 |
Options default term | 3 years 3 months 4 days | ||||||
Number of options expired during period | 25,383 | 35,741 | |||||
2014 Equity Compensation Plan [Member] | |||||||
Number of reserved for future issuance | 152,101 | 279,101 | 31,000 | 27,000 | |||
2014 Equity Compensation Plan [Member] | Common Stock [Member] | |||||||
Number of reserved for future issuance | 310,101 | ||||||
2014 Equity Compensation Plan [Member] | Majority Stockholders [Member] | |||||||
Number of reserved for future issuance | 75,000 | ||||||
2014 Equity Compensation Plan [Member] | Stockholders [Member] | |||||||
Number of reserved for future issuance | 25,000 | ||||||
Reserved shares description | On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year. | ||||||
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | |||||||
Percentage price per share of options granted of fair market value | 10.00% | ||||||
Options default term | 10 years | ||||||
Option vested term | 4 years | ||||||
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees [Member] | Maximum [Member] | |||||||
Percentage price per share of options granted of fair market value | 100.00% | ||||||
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | 10% Stockholder [Member] | Maximum [Member] | |||||||
Percentage price per share of options granted of fair market value | 110.00% | ||||||
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees, Directors, Advisors and Consultants [Member] | Maximum [Member] | Non-statutory Stock Options and Restricted Stock [Member] | |||||||
Percentage price per share of options granted of fair market value | 100.00% |
Stock Option Plans - Schedule o
Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Options Outstanding, Beginning balance | 166,505 | 202,246 |
Options Exercisable, Beginning balance | 166,536 | 192,108 |
Options, Canceled | ||
Options, Granted | ||
Options, Exercised | ||
Options, Expired | (25,383) | (35,741) |
Options Outstanding, Ending balance | 141,122 | 166,505 |
Options Exercisable, Ending balance | 135,934 | 166,536 |
Weighted Average Exercise Price, Outstanding, Beginning balance | $ 85.81 | $ 80.14 |
Weighted Average Exercise Price, Exercisable, Beginning balance | 87 | 81.32 |
Weighted Average Exercise Price, Outstanding, Ending balance | 99.08 | 85.81 |
Weighted Average Exercise Price, Exercisable, Ending balance | $ 100.89 | $ 87 |
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning | 3 years 6 months 7 days | |
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning | 3 years 3 months 4 days | |
Weighted Average Remaining Contractual Term in Years, Outstanding Ending | 3 years 5 months 1 day | 3 years 1 month 20 days |
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending | 3 years 3 months 8 days | 2 years 11 months 23 days |
Aggregate Intrinsic Value, Outstanding Beginning balance | ||
Aggregate Intrinsic Value, Exercisable Beginning balance | ||
Aggregate Intrinsic Value, Outstanding Ending balance | ||
Aggregate Intrinsic Value, Exercisable Ending balance |
Stock Option Plans - Schedule_2
Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Non-vested, Options Outstanding, Beginning balance | 5,969 | 10,138 |
Non-vested, Options Granted | ||
Non-vested, Options Vested | (781) | (4,169) |
Non-vested, Options Canceled | ||
Non-vested, Options Outstanding, Ending balance | 5,188 | 5,969 |
Stock Option Plans - Schedule_3
Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Service provider compensation | $ 10,625 | $ 44,375 |
Employee compensation | 39,687 | 39,688 |
Total | $ 50,312 | $ 84,063 |
Warrants (Details Narrative)
Warrants (Details Narrative) - USD ($) | Jan. 11, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Jan. 12, 2021 |
Discount on convertible notes | $ 104,347 | $ 104,347 | |||
Stock compensation expense | 50,312 | $ 84,063 | |||
Stock issuance cost | 76,460 | ||||
Warrant [Member] | |||||
Stock compensation expense | $ 75,000 | $ 75,000 | |||
Warrants expired | 85,171 | ||||
Placement Agent Warrants [Member] | |||||
Warrants to purchase of common stock shares | 700 | ||||
Warrant price per share | $ 0.01 | ||||
Warrants, term | 12 months | ||||
Placement Agent Warrants [Member] | Warrant [Member] | |||||
Warrant price per share | $ 5 | ||||
Warrants, term | 5 years | ||||
Stock issuance cost | $ 903 | ||||
Convertible Note Payable [Member] | |||||
Warrants to purchase of common stock shares | 85,000 | ||||
Warrant price per share | $ 5 | ||||
Convertible Note Warrants [Member] | |||||
Warrants to purchase of common stock shares | 230,670 | ||||
Warrants, term | 5 years | ||||
Discount on convertible notes | $ 110,450 | $ 295,854 | |||
Convertible Note Warrants [Member] | Minimum [Member] | |||||
Warrant price per share | $ 4.50 | ||||
Convertible Note Warrants [Member] | Maximum [Member] | |||||
Warrant price per share | $ 10 |
Warrants - Schedule of Stock Wa
Warrants - Schedule of Stock Warrants Activity (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Jun. 30, 2020 | Sep. 30, 2020 | Dec. 31, 2020 | |
Warrants, Granted | 34,564 | 12,756 | 34,248 | 25,952 | 45,732 |
Warrant [Member] | |||||
Warrants, Outstanding, Beginning balance | 780,935 | 516,748 | 516,748 | 516,748 | 516,748 |
Warrants Exercisable, Beginning balance | 780,935 | 516,748 | 516,748 | 516,748 | 516,748 |
Warrants, Canceled | |||||
Warrants, Granted | 120,264 | 349,358 | |||
Warrants, Exercised | |||||
Warrants, Expired | (85,171) | ||||
Warrants, Outstanding, Ending balance | 901,199 | 780,935 | |||
Warrants Exercisable, Ending balance | 900,849 | 780,935 | |||
Weighted Average Exercise Price, Outstanding, Beginning | $ 15.47 | $ 24.6 | $ 24.6 | $ 24.6 | $ 24.6 |
Weighted Average Exercise Price, Exercisable, Beginning | 15.47 | $ 24.6 | $ 24.6 | $ 24.6 | 24.6 |
Weighted Average Exercise Price, Outstanding, Ending | 13.96 | 15.47 | |||
Weighted Average Exercise Price, Exercisable, Ending | $ 13.97 | $ 15.47 | |||
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding | 3 years 6 months 10 days | 1 year 10 months 10 days | |||
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable | 3 years 6 months 10 days | 1 year 10 months 10 days | |||
Weighted Average Remaining Contractual Term in Years, Ending Outstanding | 3 years 8 months 12 days | 3 years 6 months 10 days | |||
Weighted Average Remaining Contractual Term in Years, Ending Exercisable | 3 years 8 months 12 days | 3 years 6 months 10 days | |||
Aggregate Intrinsic Value, Outstanding, Beginning | |||||
Aggregate Intrinsic Value, Exercisable, Beginning | |||||
Aggregate Intrinsic Value, Outstanding, Ending | 25,937 | ||||
Aggregate Intrinsic Value, Exercisable, Ending | $ 25,153 |
Warrants - Schedule of Fair val
Warrants - Schedule of Fair value of Warrant Valuations (Details) - Warrant [Member] | Mar. 31, 2021 | Dec. 31, 2020 |
Expected Dividend Yield [Member] | ||
Warrants, measurement input | 0 | 0 |
Risk Free Interest Rate [Member] | Minimum [Member] | ||
Warrants, measurement input | 0.15 | 1.13 |
Risk Free Interest Rate [Member] | Maximum [Member] | ||
Warrants, measurement input | 0.92 | 1.55 |
Volatility [Member] | Minimum [Member] | ||
Warrants, measurement input | 151 | 143 |
Volatility [Member] | Maximum [Member] | ||
Warrants, measurement input | 187 | 168 |
Expected Term [Member] | Minimum [Member] | ||
Warrants term | 2 years 6 months | 2 years |
Expected Term [Member] | Maximum [Member] | ||
Warrants term | 5 years | 5 years |
Warrants - Schedule of Independ
Warrants - Schedule of Independent Directors Warrants (Details) - $ / shares | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Jun. 30, 2020 | Sep. 30, 2020 | Dec. 31, 2020 | |
Warrants and Rights Note Disclosure [Abstract] | |||||
Warrants | 34,564 | 12,756 | 34,248 | 25,952 | 45,732 |
Warrants exercise price | $ 2.25 | $ 6 | $ 2.25 | $ 3 | $ 1.70 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Effective tax statutory rate | 21.00% | 21.00% |
Basic and Diluted Net Loss Pe_3
Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Earnings Per Share [Abstract] | ||
Net Loss (Numerator) Basic loss per share, basic | $ (1,382,118) | $ (1,002,868) |
Net Loss (Numerator) Effect of dilutive securities-Common stock options, warrants, convertible notes, and preferred stock | ||
Net Loss (Numerator) Diluted loss per share, diluted | $ (1,382,118) | $ (1,002,868) |
Shares (Denominator) Basic loss per shares, basic | 794,183 | 700,879 |
Shares (Denominator) Effect of dilutive securities-Common stock options, warrants, convertible notes, and preferred stock | ||
Shares (Denominator) Diluted loss per shares, diluted | 794,183 | 700,879 |
Per share amount Basic loss per share, basic | $ (1.74) | $ (1.43) |
Per share amount Effect of dilutive securities-Common stock options, warrants, convertible notes, and preferred stock | ||
Per share amount Diluted loss per share, diluted | $ (1.74) | $ (1.43) |
Basic and Diluted Net Loss Pe_4
Basic and Diluted Net Loss Per Share - Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Total common stock equivalents | 1,740,640 | 1,092,692 |
Common Stock Warrants [Member] | ||
Total common stock equivalents | 901,199 | 447,036 |
Common Stock Preferred Stock [Member] | ||
Total common stock equivalents | 10,172 | |
Common Stock Convertible Notes [Member] | ||
Total common stock equivalents | 688,147 | 443,410 |
Common Stock Options [Member] | ||
Total common stock equivalents | 141,122 | 202,246 |
Leases (Details Narrative)
Leases (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | ||||
Aug. 31, 2019 | Jan. 31, 2018 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Aug. 13, 2010 | |
Operating lease, right-to-use asset | $ 962 | |||||
ASU No. 2016-02 [Member] | ||||||
Operating lease, right-to-use asset | 962 | |||||
Operating lease, liabilities | $ 962 | |||||
Vehicle Lease Arrangement [Member] | ||||||
Lease, term | 3 years | |||||
Total monthly payment | $ 1,002 | $ 1,619 | ||||
Lease expense | 1,783 | $ 3,754 | ||||
Office Lease [Member] | ||||||
Lease, term | 45 days | |||||
Rent expenses | $ 9,255 | $ 8,989 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | May 12, 2021 | May 11, 2021 | Jul. 14, 2020 | Mar. 31, 2021 |
Debt instrument interest rate | 12.00% | |||
Debt extended maturity date | Jul. 31, 2020 | |||
Subsequent Event [Member] | ||||
Debt instrument principal amount | $ 500,000 | |||
Debt extended maturity date | Jun. 11, 2021 | |||
Extension fee | $ 25,000 | |||
Economic Injury Disaster Loan [Member] | April 20, 2021 [Member] | ||||
Debt instrument principal amount | $ 500,000 | |||
Debt instrument interest rate | 3.75% | |||
Debt installment payments | $ 2,505 | |||
Debt instrument, payment terms | Installment payments, including principal and interest, of $2,505 per month, will begin eighteen (18) months from the date of issuance. The balance of principal and interest will be payable thirty (30) years from the date of issuance. The loan is secured by all tangible and intangible assets of the Company and personally guaranteed by the Company's Chief Executive Officer as an individual. |